----
Current ValuationThe current P/E ratio is 38.54, above the reasonable range, cheaper than 6.39% of the time in the past 3 years, and the industry ranks 27/52, the industry Median 6.64.
38.54xP/E
HK$5.68Stock price
HK$0.15Earnings per share
38.54xP/E
Stock priceHK$5.68Earnings per shareHK$0.15
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 25.22x
- Typical range
- 16.89x–35.07x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 6.64x
013263952
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 6.64x
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
01276HKHENGRUI PHARMA | 36.66x | 20.90% | HK$326.15B |
01177HKSBP GROUP | 38.54x | 110.57% | HK$106.03B |
06996HKANTENGENE-B | 38.95x | 246.23% | HK$2.40B |
03737HKZHONGZHIPHARM | 33.20x | -- | HK$673.61M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
